{"id":"https://genegraph.clinicalgenome.org/r/88932e6b-4af6-42d6-a223-537f281c74e7v1.1","type":"EvidenceStrengthAssertion","dc:description":"*EZH2* was first reported in relation to autosomal dominant Weaver syndrome in 2011 (PMID: 22190405). Weaver syndrome (WS) is a rare multisystem disorder characterized by tall stature, a typical facial appearance, and variable intellectual disability. Additional features may include camptodactyly, advanced bone age, soft doughy skin, umbilical hernia, and a low hoarse cry (PMIDs: 22190405, 23865096, 24214728). *EZH2* variants have also been observed in individuals with overgrowth who did not have a clinical diagnosis of Weaver syndrome (PMIDs: 22190405, 24214728). *EZH2* variants, primarily missense, as well as a small number of nonsense, frameshift, and in-frame insertion or deletion variants, have been identified in over 50 individuals with Weaver syndrome or overgrowth (PMIDs: 22177091, 22190405, 24214728, 32243864). Truncating variants are uncommon and to date have only been identified in the last or penultimate exon (PMID: 24214728, ClinVar variation ID: 207471). Only 11 probands are included in this curation because the maximum score for genetic evidence has been reached.\n\n*EZH2* encodes a histone methyltransferase. Pathogenic variants in EZH2 generate a highly specific DNA methylation signature (PMID: 32243864). The disease mechanism is loss of function (PMIDs: 26694085, 29244146, 32243864). However, the fact that truncating variants have only been reported in the last or penultimate exon and may therefore escape nonsense-mediated decay suggests that they may not act through haploinsufficiency (PMID: 22190405, 24214728). This gene-disease relationship is also supported by experimental evidence, including protein interaction, functional alterations, and mouse model studies (PMIDs: 15225548, 26694085, 29244146, 32243864).\n \nIn summary, there is definitive evidence supporting the relationship between *EZH2* and Weaver syndrome. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on August 3, 2022 (SOP Version 9).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/88932e6b-4af6-42d6-a223-537f281c74e7","GCISnapshot":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2022-09-21T12:39:15.472Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2022-08-03T16:00:00.000Z","role":"Approver"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3a5e531-946c-47a1-a59a-6e0b80cdc69c","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3a5e531-946c-47a1-a59a-6e0b80cdc69c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32243864","allele":{"id":"https://genegraph.clinicalgenome.org/r/fcfad976-3045-48e2-8340-b932eabdd5c2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.1876G>A (p.Val626Met)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA271506"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/d3a5e531-946c-47a1-a59a-6e0b80cdc69c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the L695L variant shows a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0a5ae2ab-fdf8-49ba-bd40-117498b69721","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0a5ae2ab-fdf8-49ba-bd40-117498b69721_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","allele":{"id":"https://genegraph.clinicalgenome.org/r/dbcdd620-8cda-4a6b-a553-334d55096078","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.466A>G (p.Lys156Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369721412"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/0a5ae2ab-fdf8-49ba-bd40-117498b69721_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the K156E variant shows a methylation signature similar to known EZH2 pathogenic variants.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/6584f3f4-6870-45e5-a26c-9b40002336fd","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6584f3f4-6870-45e5-a26c-9b40002336fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24214728","allele":{"id":"https://genegraph.clinicalgenome.org/r/109b31d1-6fae-433f-9a34-b6113da7038c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2233G>A (p.Glu745Lys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA345008"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/6584f3f4-6870-45e5-a26c-9b40002336fd_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, p.Glu745Lys variant showed a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864)\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5f348459-69aa-475f-912d-8206f0db2f70","type":"EvidenceLine","dc:description":"An additional 0.5pt was awarded because the variant is recurrent as it was found in 4 unrelated individuals with Weaver syndrome (PMID: 32243864).","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5f348459-69aa-475f-912d-8206f0db2f70_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","allele":{"id":"https://genegraph.clinicalgenome.org/r/8263c9fb-5992-4ac0-9fdb-772370656edf","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2050C>T (p.Arg684Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA271512"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/5f348459-69aa-475f-912d-8206f0db2f70_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the R684C variant showed a methylation signature similar to known EZH2 pathogenic variants.","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/a17c52b3-9b5c-400b-9107-ab93f9329eba","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a17c52b3-9b5c-400b-9107-ab93f9329eba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22177091","allele":{"id":"https://genegraph.clinicalgenome.org/r/178ed49b-3a9e-4e96-8f83-5a6742185e95","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.457_459del (p.Tyr153del)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/30198"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/a17c52b3-9b5c-400b-9107-ab93f9329eba_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the p.Tyr153del variant shows a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/68408985-252b-4097-8536-715c2c9bfae6","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/68408985-252b-4097-8536-715c2c9bfae6_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24214728","allele":{"id":"https://genegraph.clinicalgenome.org/r/a5287332-af4e-47b1-b3ad-d2fe85591e5f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.443A>G (p.Glu148Gly)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369721512"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/68408985-252b-4097-8536-715c2c9bfae6_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, p.Glu148Gly variant showed a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864)","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/035a1507-98ac-4762-bf98-ee7828b1f9d1_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","rdfs:label":"Case 2 family","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/035a1507-98ac-4762-bf98-ee7828b1f9d1","type":"Family","rdfs:label":"Case 2 family","member":{"id":"https://genegraph.clinicalgenome.org/r/de4dcea9-d99f-4d38-8d64-e55caac148a5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","rdfs:label":"case 2 (III:2)","allele":{"id":"https://genegraph.clinicalgenome.org/r/dbcdd620-8cda-4a6b-a553-334d55096078"},"firstTestingMethod":"Sanger sequencing","phenotypes":["obo:HP_0100774","obo:HP_0001328","obo:HP_0000256","obo:HP_0000098"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/0a5ae2ab-fdf8-49ba-bd40-117498b69721_variant_evidence_item"}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":6,"phenotypes":["obo:HP_0001328","obo:HP_0100774","obo:HP_0000098","obo:HP_0000256"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/de4dcea9-d99f-4d38-8d64-e55caac148a5"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/2691750f-374a-4cdc-a8f0-b6626eced82c","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2691750f-374a-4cdc-a8f0-b6626eced82c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","allele":{"id":"https://genegraph.clinicalgenome.org/r/43fb90d5-91e5-4f0b-bce5-2d64e50a323f","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2204_2211dup (p.Ala738fs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/1700628"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/8a328f67-7b4e-40f8-8f74-5fe2eed44ac0","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a328f67-7b4e-40f8-8f74-5fe2eed44ac0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22190405","allele":{"id":"https://genegraph.clinicalgenome.org/r/943bea9a-4eb4-469f-9daa-b0d81ae7038c","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2084C>T (p.Ser695Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369712199"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/8a328f67-7b4e-40f8-8f74-5fe2eed44ac0_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the L695L variant shows a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864).","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/3b499294-b8e3-4812-be6a-0122e8697ba7","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b499294-b8e3-4812-be6a-0122e8697ba7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22177091","allele":{"id":"https://genegraph.clinicalgenome.org/r/68ae9359-e074-4199-a05f-c6d5912aee83","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.394C>T (p.Pro132Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA259762"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/3b499294-b8e3-4812-be6a-0122e8697ba7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the p.Pro132Ser variant shows a methylation signature similar to known EZH2 pathogenic variants [PMID: 32243864]","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/355226f1-7626-447d-8c42-7166622ed0bc","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/355226f1-7626-447d-8c42-7166622ed0bc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24214728","allele":{"id":"https://genegraph.clinicalgenome.org/r/f411da41-2fda-4255-b414-772f980ae095","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2222A>G (p.Tyr741Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA369711806"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/355226f1-7626-447d-8c42-7166622ed0bc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, p.Tyr741Cys variant showed a methylation signature similar to known EZH2 pathogenic variants (PMID: 32243864)\n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/51830e75-5200-444a-919c-9d38a386353a","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/51830e75-5200-444a-919c-9d38a386353a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22177091","allele":{"id":"https://genegraph.clinicalgenome.org/r/54a6b980-4a48-4ce2-87ba-ae06555656ec","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_004456.5(EZH2):c.2080C>T (p.His694Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA259759"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Heterozygous"}},{"id":"https://genegraph.clinicalgenome.org/r/51830e75-5200-444a-919c-9d38a386353a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"In a genome-wide DNA methylation assay, the L695L variant shows a methylation signature similar to known EZH2 pathogenic variants [PMID: 32243864]","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/378ab373-0886-4eb8-9d59-aea484e4a6b3","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9c0bf17-3f59-47cc-8f65-c2829a12378c","type":"Finding","dc:description":"EZH2 interacts directly with EED and is found in a protein complex with SUZ12, which forms the PRC2 complex (Cao et al., 2004 PMID 15225548). Pathogenic variants in EED (Cohen et al., 2015) and SUZ12 (Magawa et al., 2017) are linked to overgrowth and intellectual disability. Consistently, EZH2 is associated with overgrowth syndrome and intellectual disability.\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/15225548","rdfs:label":"EZH2 directly interacts with EED","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/fd5f4239-640c-4c5a-b2d1-6de91ffd0aef","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f8382588-f6f3-43fc-bd6f-ff56af35f2f5","type":"FunctionalAlteration","dc:description":"Weaver syndrome associated EZH2 variants showed reduced methyltransferase activity in vitro.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26694085","rdfs:label":"EZH2 mutants in vitro methyltransferase activity"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/e0e362b3-8caa-48c7-8827-071b36ab9bb5","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/33c785e0-f10c-46f5-9593-d324c7fe0d31","type":"FunctionalAlteration","dc:description":"Blood samples from weaver syndrome patient with EZH2 variant showed distinct DNA Methylation Signature that are different from control samples ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32243864","rdfs:label":"Methylation assay using patient blood"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/5dcf5941-6076-4486-94be-7ba3944abaee_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/462f139f-0ed6-47d9-be0c-b12c2f0d6955","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/4d825b1f-32d8-4177-a31e-77ef3f6eea80","type":"Finding","dc:description":"Nuclear extracts from cells transfected with mutant EZH2 showed reduced methyltransferase activity. in addition, Immunostaining of E14.5 embryos demonstrated that dimethyl-H3K27 levels were decreased in heterozygous embryos, consistent with reduced H3K27 methylation in humans with WS.\n\n\n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29244146","rdfs:label":"DNA methylation in cultured chondrocytes from EZH2 ko mice","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityCellCultureModelOrganismCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0d754b73-68ce-4b76-aa6a-69c692929643","type":"EvidenceLine","dc:description":"The score was downgrade because the weight effect is only significant in female mice. Furthermore, no effect of the mutant on the brain of mice was demonstrated.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d1ca139a-812d-4404-88e6-fa69e56dbd1d","type":"Finding","dc:description":"Similar to humans with pathogenic EZH2 variants, the EZH2 p.V626M mice showed mild overgrowth. However, the overgrowth phenotype was significantly different from controls in female mice only. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29244146","rdfs:label":"EZH2 p.V626M mouse model","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":3.5}],"evidenceStrength":"Definitive","sequence":5021,"specifiedBy":"GeneValidityCriteria9","strengthScore":15.5,"subject":{"id":"https://genegraph.clinicalgenome.org/r/GfRPXSSdyz4","type":"GeneValidityProposition","disease":"obo:MONDO_0010193","gene":"hgnc:3527","modeOfInheritance":"obo:HP_0000006"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_5dcf5941-6076-4486-94be-7ba3944abaee-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}